A novel blood test for tuberculosis prevention and treatment
| Autor: | Mark Hatherill, Adam Penn-Nicholson, Tom Sumner, Thomas J. Scriba, Richard G. White |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Pediatrics medicine.medical_specialty Tuberculosis Antitubercular Agents lcsh:Medicine Disease Polymerase Chain Reaction Tuberculosis prevention and treatment 03 medical and health sciences Early Medical Intervention Humans Mass Screening Medicine Blood test lcsh:R5-920 medicine.diagnostic_test business.industry Tuberculosis prevention Incidence (epidemiology) lcsh:R General Medicine World population medicine.disease Virology Preventive therapy Early Diagnosis 030104 developmental biology RNA Transcriptome business lcsh:Medicine (General) Infectious agent |
| Zdroj: | South African Medical Journal, Vol 107, Iss 1, Pp 4-5 (2017) SAMJ: South African Medical Journal, Volume: 107, Issue: 1, Pages: 4-5, Published: JAN 2017 |
| ISSN: | 2078-5135 0256-9574 |
| Popis: | Almost 1 in every 100 South Africans is diagnosed with active tuberculosis (TB) disease every year, an incidence that ranks among the highest of the world’s 22 high-TB-burden countries; TB accounted for an astounding 14.6% of deaths among 15 - 44-year-olds in South Africa (SA) in 2014. Globally, TB is recognised as the leading cause of mortality by an infectious agent, with 1.4 million deaths and 10.4 million new TB cases in 2015. Although most forms of TB are treatable, prompt diagnosis is challenging and passive case-finding approaches have failed to control the epidemic. The estimated 80% of SA adults who are latently infected with Mycobacterium tuberculosis form a massive reservoir for future reactivation cases. Indeed, even if all new M. tuberculosis infections were prevented, the incidence of TB stemming from the global reservoir of 1.7 billion latently infected people (23% of the world population) would be 16.5 per 100 000 person-years in 2035, falling short of the 2050 target for eradicating TB. As preventive therapy at this scale is not feasible, no single current intervention is likely to achieve the goals of The End TB Strategy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|